# Cosiporfin Sodium for Injection Photodynamic Therapy

Source: https://onco.cc/trials/nct07398339/  
OnCo record `nct07398339` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine and Cisplatin in biliary tract cancer, run by Shanghai Guangsheng Biopharmaceutical Co., Ltd, now recruiting.

## Summary

Cosiporfin Sodium for Injection Photodynamic Therapy is a phase 2 interventional study registered as NCT07398339 by Shanghai Guangsheng Biopharmaceutical Co., Ltd, with 30 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection and Cisplatin for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07398339
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase IIa Clinical Study Evaluating the Preliminary Efficacy and Safety of Sodium Porphyrin Injection Combined With Photodynamic Therapy Plus Gemcitabine and Cisplatin Chemotherapy in Patients With Advanced Extrahepatic Cholangiocarcinoma With Biliary Obstruction
- Sponsor: Shanghai Guangsheng Biopharmaceutical Co., Ltd
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07398339: https://clinicaltrials.gov/study/NCT07398339

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07398339.json